Yes, it's looking good. This play is still so unknown. I mentioned it to a fellow who deals with the FDA and the response was that it's safety needs to be heavily scrutinized. Well, (1) I'm not sure what could be safer than our peptide (2) the safety of the drug/peptide combo will fall on the investigating pharma after we've been paid licensing fees. I think many don't have the vision to see how big this play can be. Anyway, I've always maintained that one can stil buy after the first licensing announcement and make plenty of $$. The play will be derisked and the first licensing announcement will be the first in a line of dominos to fall. I've got a full complement of shares but reserve the right to add more :) Bfw